🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Last day to vote for the AACR elections! Vote for Dr Yap even though he is a Liverpool fan!

Timothy A. Yap, MBBS, PhD, has been appointed editor-in-chief of Clinical Cancer Research. Dr. Yap is co-director for the AACR/ASCO Methods in Clinical Cancer Research Workshop and a past cochair of the AACR Annual Meeting Clinical Trials Committee. Learn more: brnw.ch/21wQUKi

We are pleased to announce that Timothy A. Yap, MBBS, PhD, of The University of Texas MD Anderson Cancer Center, has been appointed Editor-in-Chief of Clinical Cancer Research. Learn More: brnw.ch/21wQV12

Great impromptu meeting of the #sarcoma minds to talk about some cool new findings in the lab MD Anderson Cancer Center AlexanderLazarMDPhD

Featured in Healthgrades w/ @elise_efn sharing our journey as physicians working together at MD Anderson Cancer Center 💪 Easing psychological burdens & treating patients together 💡Bouncing patient care ideas off each other 🔬Supporting each other’s research resources.healthgrades.com/pro/husband-wi…

#CTOS2025 registration and abstract submission system is open! 🎉Don't miss the biggest #sarcoma meeting and unique celebration of CTOS's 30th anniversary! 🗓️ We are waiting for your abstracts until Jun 20th! More details on the meeting website ⏩ ctos.org/Meeting/2025An…

My Captain! 🫡

This new editorial by Elise Nassif Haddad et al comments on the recent study led by Michael Cecchini & Dr Mary Jo Pilat on the PARP inhibitor olaparib in advanced pretreated IDH1/2-mutant tumors: acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… OncoAlert #cholangiocarcinoma

#ASCO25 is very different this year👩‍🍼Fadi Haddad, MD ASCO

Congrats to Stephanie presenting our work on optimal treatment of uterine #leiomyosarcoma #ASCO25 #endcancer MD Anderson Cancer Center

Presented by Dr. Tim Yap at #ASCO25: BNT142, a bispecific antibody therapy, shows manageable safety and early anti-tumor activity in CLDN6-positive cancers, including ovarian and testicular tumors. First-in-human results are encouraging. #EndCancer

HMPL-306, a novel small-molecular dual inhibitor of IDH1 and IDH2 mutations is safe and well tolerated and showed durable responses in patients with lower-grade gliomas, says our Dr. Jordi Rodon Ahnert in an oral presentation at #ASCO25. ASCO #EndCancer

Twenty year survival of advanced gastrointestinal stromal tumours treated with imatinib Exploratory long-term follo… pubmed.ncbi.nlm.nih.gov/40447230/

Busy morning 🎬 with OncLive.com It was great to represent MD Anderson Cancer Center and our #MDACC_BMO_Department Session #1 was information packed about #ESR1m and the evolving treatment landscape Session #2 was a panel discussion about the expanding field of ctDNA/MRD testing in

Spatial transcriptomics revealed two new subtypes of leiomyosarcoma that are potential prognostic biomarkers for this rare and aggressive type of soft tissue sarcoma. Our fellow, Dr. Ryan Denu, MD, PhD presented results at an #ASCO25 session moderated by our Dr. Elise Nassif Haddad. Read more:

“The heterogeneity of sarcomas coupled with their rarity makes them hard to study, and conflicting results from studies add further complexity,” says our Dr. @VinodRavi in an education session on neo/adjuvant therapy for soft tissue sarcoma at #ASCO25. ASCO #EndCancer

Kudos to ASCO for being mommy-friendly! Nursing rooms are: ✅close to the main conference rooms ✅private ✅well equipped and comfy Bonus point for best badge ever! 🥰 #ASCO25 #family #breastfeeding #workingmom

#ASCO25 was different this year with Alexandre joining us, as the youngest ASCO attendee 👶 📢 Shoutout to Elise Nassif Haddad & all working mothers who navigate everyday the scientific & medical field while taking care of their families 🥇

👏 Congratulations Ryan Denu, MD, PhD on your oral presentation at #ASCO25 🥇Great to see Elise Nassif Haddad from MD Anderson Cancer Center chairing fhe #sarcoma session this morning at ASCO

After the inspiring ASCO meeting we are looking forward to meeting all the sarcoma family again at #CTOS2025! Patient advocacy groups are valuable members of our community! ⬇️Check the invitation from Kathrin Schuster from SPAGN and CTOS Outreach Committee